Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September

Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027

Reprogramming the Immune System to Treat Pulmonary Fibrosis

3:00 pm - Wednesday 30th September 2026

Exploring the role of the immune system as a key driver of pulmonary fibrosis and identifying opportunities to intervene fibrotic progression
Introducing DCD-80, a novel small-molecule immunotherapy designed to reprogram the immune system and induce antifibrotic signalling

Speakers:

Robin Mansukhani

ceo

Deciduous Therapeutics

Reprogramming the Immune System to Treat Pulmonary Fibrosis

Reprogramming the Immune System to Treat Pulmonary Fibrosis

Speakers:

Venue

Map

Contact

Join Our Team

About Us

Explore Our Conferences

Stay Connected

Search

Organized By